The size of the Asia Pacific Checkpoint Inhibitors Market was valued at USD 2.61 billion in 2022. It is projected to reach USD 9.61 billion by 2027, growing at a CAGR of 29.8% from 2022 to 2027.
Due to an increase in the incidence of many types of cancer, more awareness of checkpoint inhibitors for cancer treatment, a higher number of pipeline medications, and increased use of immune checkpoint inhibitor drugs, checkpoint inhibitors have seen increased demand. In addition, the market for Asia Pacific checkpoint inhibitors is predicted to rise due to the adoption of unhealthy lifestyles, rising cancer cases, and genetic modification/alteration. Furthermore, the checkpoint inhibitors market is growing due to a rise in cancer prevalence across geographies and increased awareness of checkpoint inhibitors. Furthermore, technical developments in cancer screening procedures, rising healthcare expenses, more significant government measures to combat cancer, and increased public awareness are projected to propel the market forward.
Furthermore, the market is driven by the growing elderly population and technological developments in cancer screening and detection. In the market for checkpoint inhibitors, there is fierce rivalry, which is pushing acquisitions and in-licensing deals. The top checkpoint inhibitors market players are attempting to diversify and grow their product portfolios. Furthermore, firms are forging partnerships to combine their efforts to produce combination medicines. Several small firms are attempting to tap into the checkpoint inhibitors market's potential by developing next-generation checkpoint inhibitors therapies. The checkpoint inhibitors market is expected to grow during the forecast period due to the increased number of patients, raising public awareness, and earlier cancer detection utilizing technologically enhanced screening technologies.
However, the high cost of product research and development raises the cost of the finished product and associated therapy. This factor is projected to stifle the checkpoint inhibitors market's growth. Furthermore, regulatory price caps have been imposed due to the high cost of checkpoint inhibitors. The lack of cost-effective cancer medicines has influenced the population's health and resulted in a low average life expectancy. The checkpoint inhibitors market is restrained by advancements in cancer therapy and an increase in the population with immune system diseases. Still, strict FDA requirements for new drug approval and adverse effects would hurdle to market expansion. The checkpoint inhibitor market is also projected to be hampered by regulatory price controls for checkpoint inhibitors.
This research report on the Asia Pacific checkpoint inhibitors market has been segmented and sub-segmented into the following categories.
By Drug:
By Application:
By Country:
Geographically, due to the numerous research collaborations between international players and companies from this region, Asia Pacific is the fastest expanding region in the checkpoint inhibitors market worldwide. Furthermore, due to its large population base, increased awareness of advanced immunotherapy increased cancer incidence, and improved healthcare infrastructure, Asia-Pacific presents lucrative opportunities for key players in the checkpoint inhibitors market.
The high prevalence of cancer in China, Japan, and India is projected to fuel demand for immunological checkpoint inhibitors in the near future. In addition, the presence of major key players and significant investment in R&D activities to develop new products with fewer side effects and generic drugs, as well as government incentives to encourage innovation to reduce the growing disease burden, are likely to provide more opportunities for the ICI market to grow during the forecast period.
KEY MARKET PLAYERS:
Companies playing a vital role in the Asia Pacific checkpoint inhibitors market profiled in this report are Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Type
5.1.1 Introduction
5.1.2 PD-1 inhibitors
5.1.3 PD-L1 inhibitors
5.1.4 CTLA-4
5.1.5 Chimeric Antigen Receptor T-cell
5.1.6 Others
5.1.7 Y-o-Y Growth Analysis, By Drug Type
5.1.8 Market Attractiveness Analysis, By Drug Type
5.1.9 Market Share Analysis, By Drug Type
5.2 Application
5.2.1 Introduction
5.2.2 Lung cancer
5.2.3 Renal cancer
5.2.4 Blood cancer
5.2.5 Bladder Cancer
5.2.6 Hodgkin lymphoma
5.2.7 Melanoma
5.2.8 Others
5.2.9 Y-o-Y Growth Analysis, By Application
5.2.10 Market Attractiveness Analysis, By Application
5.2.11 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Drug Type
6.1.3.3 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Drug Type
6.1.4.3 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Drug Type
6.1.5.3 By Application
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Merck & Co., Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Bristol-Myers Squibb
8.3 Roche
8.4 AstraZeneca
8.5 Ono Pharmaceutical Co., Ltd.
8.6 Juno Therapeutics
8.7 Novartis International AG
8.8 Kite Pharma
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
